Erectile dysfunction is a common (affecting 10-20 million men in the USA) and multifactorial disease due to organic and/or psychological factors that strongly impairs the quality of life in man. During the past decade many advances in the understanding of the pathophysiology of erectile dysfunction have been made and new therapeutic strategies have become available. It has been established that an insufficient production of nitric oxide by penile nerve terminals and/or vascular endothelium may result in an impaired erection or complete impotence. Nowadays, intracavernous injection of vasoactive drugs represents a standardized approach for the diagnosis, and the treatment of choice, for erectile dysfunction, but is not widely accepted by the patients. The possibility of treating erectile dysfunction with intraurethral administration of prostaglandin-E 1 has recently become available in the USA, and is a therapy more acceptable to the patients. Other noninvasive medical therapies are undergoing evaluation.
Introduction
Erectile dysfunction (ED) is defined as the inability of the male to attain and maintain erection of the penis sufficient to permit satisfactory sexual intercourse (NIH Consensus Conference, 1993) . However, sexual complaints not included in this definition frequently include a loss of rigidity after vaginal intromission and early or premature ejaculation. These alterations of sexual behaviour may precede fully developed ED and should be adequately considered for medical treatment. Other sexual dysfunctions such as reduced libido, ejaculatory disturbances, reduced orgasmic sensation and infertility may accompany ED (Korenman, 1995) . ED represents a social problem occurring in ~50% of the general male population aged between 40 and 70 years (Feldman et al., 1994) and may be caused by organic and/or psychological disorders, the former being prevalent (65 versus 35%) according to recent studies (Benet and Melman, 1995) . The incidence of ED increases with age (75% >70 years old), and the disease frequently occurs in the presence of organic diseases such as chronic renal (20-100%) or hepatic failure (50-70%), diabetes (27.5-60%), hypertension (46%), Peyronie's disease (35%), hypercholesterolaemia/atherosclerosis (33%), ischaemic heart disease (16%) and depression (Schiavi and Rehman, 1995) . Almost 30% of ED is due to the presence of systemic disease which affects the blood supply to the penis. Cigarette smoking does not represent a direct cause but may be a risk factor for ED (Feldman et al., 1994) . Endocrine disorders have been claimed not to be a cause of ED. However, in some studies, low testosterone concentrations have been shown to be present in >15% of patients complaining of erectile failure (Govier et al., 1996) and hyperprolactinaemia has been indicated to be the cause of ED in 2-3% of impotent men (Baskin, 1989) . Neurogenic impotence is not unusual (3-10%) and is observed concomitant with multiple sclerosis, discopathies of lumbosacral tract, after prostatectomy and following spinal cord, pelvic, perineal or penile traumas (Berger et al., 1993) . Psychological causes are frequent (30-40%) and include interactive-experiential problems (depressive-anxious behaviour, religious pressure, lifestyle changes, psychological trauma, child abuse etc.) and/or relationship disorders (performance anxiety, sexual incompatibility, loss of attraction, fears of intimacy etc.) (Cole, 1993) . Finally, a wide variety of drugs has erectolytic effects (Meinhardt et al., 1997) and the use of drug therapies must be always carefully investigated in the medical history of patients with erectile dysfunction (Table I) . The brain is the major sexual organ. Androgens stimulate libido and, together with a large array of neuropeptides, regulate sexual behaviour in the brain. In the presence of an adequate androgen milieu, the brain drives the sexual response by integrating external erotic stimuli (received through the five senses or erotic fantasies), and processes them into the medial-pre-optic area (MPOA) of the hypothalamus (psychogenic erection) (Figure 1 ). Specific amines and neuropeptides are involved in the processing mechanisms which lead to activation of descending pathways to the spinal centres of erection. The main neurochemicals of erectile response include gonadotrophinreleasing hormone (GnRH), oxytocin, α-melanocytestimulating hormone (α-MSH) and substance P which stimulate, and corticotrophin-releasing hormone (CRH), β-endorphin, prolactin and neuropeptide Y, which inhibit sexual behaviour (Dornan and Malsbury, 1989) .
GnRH plays a key role in facilitating mating behaviour in male and female primates. GnRH stimulation occurs independently from hypophyseal luteinizing hormone (LH) release and subsequent testicular testosterone production (Mortimer et al., 1974) , indicating that its effect is central, likely mediated by GnRH receptors located in limbic structures (King and Anthony, 1984; Reubi and Mauret, 1985) .
Oxytocin is one of the most potent stimulators of sexual drive as well as penile erection in rodents (Carter, 1992) . Oxytocin-immunoreactive neurons are mainly located in the paraventricular (PVN) and supraoptic nuclei of the hypothalamus, and oxytocin receptors have been identified in the brain areas related to the control of sexual behaviour and reproduction (i.e. ventromedial hypothalamus, bed nucleus of the stria terminalis, central amygdala, anterior olfactory nucleus, lateral septum, ventral subiculum and dorsal motor nucleus of the vagus) (Argiolas, 1992) . The binding of oxytocin to its receptors in these areas of the brain appears to be modulated by gonadal steroids (Insel et al., 1993) . Oxytocin mediates the erectogenic effects of systemic administration of apomorphine and other dopaminergic drugs. Indeed, dopamine-induced erections in the male rat occur via stimulation of oxytocin production upon binding to dopaminergic-2 (D 2 ) receptors located on oxytocin neurons, and are prevented by the intracerebroventricular injection of selective oxytocin-antagonists (Melis et al., 1994) . The sites of oxytocin action in inducing erectile response appear to be the PVN and the spinal cord. Oxytocin injection directly into the PVN induces penile erections in rodents, and the chemical destruction of PVN abolishes the oxytocin-induced erectile response (Arletti et al., 1992) . Also, PVN has been Figure 1 . Schematic representation of central and intracavernosal mechanisms involved in the control of erection. External visual, gustative, auditory, imaginative and tactile stimuli are transmitted to the rhinencephalon, the limbic cortex and thalamic nuclei, and are integrated into the hypothalamic medial preoptic area (M-POA) where they stimulate supraspinal erections (psychogenic erection). Left box: serotonin (5HT), corticotrophin-releasing-hormone (CRH) and β-endorphin (βEP) exert inhibitory effects, while gonadotrophin-releasing-hormone (GnRH), dopamine (DA) and oxytocin (OX) are the main stimulators of psychogenic erections. Hypothalamic projections (possibly oxytocinergic) to the spinal cord control thoracolumbar sympathetic (T 11 -L 2 ) and sacral parasympathetic (S 2 -S 4 ) fibres which inhibit and stimulate erection respectively. Direct genital stimuli initiate a local neural loop leading to parasympathetic stimulation from S 2 to S 4 and reflexogenic erection. Right box: intracavernosal mechanisms of erection involve cholinergic, adrenergic and non-adrenergic non-cholinergic (NANC) nervous fibres. The main stimulators of smooth muscle cell contraction (detumescence) are norepinephrine (NE) and endothelin-1 (ET 1 ), while acetylcholine (ACH) and nitric oxide (NO) are the main mediators of smooth muscle cell relaxation and erection via reduction of intracellular calcium (Ca ++ ) content. Blood oxygen tension (pO 2 ) in the sinusoids inversely regulates smooth muscle cell transforming-growth factor-β (TGFB) expression and collagen accumulation in the pericellular spaces.
found to be the source of fibres containing neurophysin (the co-product of oxytocin and vasopressin) that directly project into lumbar spinal motor neurons. These neurons innervate the striated bulbocavernosus muscle which is responsible for penile reflexes in the male rat (Wagner and Clemens, 1993) . These studies indicate that in rats oxytocin is a facilitator of sexual behaviour at both the level of the brain and of the spinal cord. Also in humans, oxytocin has been shown to be involved in sexual response and there is good evidence for pituitary secretion of oxytocin during sexual intercourse, with peak plasma concentrations attained during the orgasmic phase (Murphy et al., 1987) .
Adrenocorticotrophic hormone (ACTH) and α-melanocyte-stimulating hormone (α-MSH) are other molecules that promote copulatory behaviour and genital responses in animal species and humans. Their effects are mediated via activation of neuronal cell bodies in the hypothalamic arcuate nucleus neurons which project into the MPOA, and via the nucleus of the solitary tract in the dorsal medulla (Carter, 1992) . ACTH 1-17 and α-MSH are potent inducers of erection in humans (Isidori et al., 1984; Wessells et al., 1996) .
The main molecules with inhibitory regulatory effects on erection include serotonin and the CRH/β-endorphin peptidergic pathway (Palkovitz, 1987) . In the brain, serotonergic innervation of the hypothalamic MPOA exerts direct inhibitory effects on sexual drive and indirect inhibition via the activation of the CRH cascade (Sirinathsinghji, 1987) . In contrast, the serotonergic stimulation of 5-HT 1c receptor subtypes in the spine has opposing effects and stimulates erection in rats (Berendsen et al., 1990) and humans (i.e. during trazodone therapy) (Foreman and Wenicke, 1990) .
CRH is the hormonal mediator of the behavioural and autonomic, as well as endocrine, responses to stress (Dufau et al., 1993) . CRH injected into the rat brain inhibits copulatory behaviour in the male and lordosis responses in the female rats (Sirinathsinghji, 1987) . The hormonal effects of CRH in the hypothalamus contribute to this action, and in particular the stimulation of β-endorphin production and the inhibition of GnRH release. Indeed, there is general agreement that β-endorphin impairs male copulatory behaviour and that its effect is exerted via inhibition of neuronal GnRH, dopamine and oxytocin secretions (Fabbri et al., 1989a,b) . Opioid antagonists are believed to prevent these effects and have been shown to be effective in stimulating erections in rodents (Gessa et al., 1979) and humans (Goldstein, 1986; Fabbri et al., 1989a) . These studies indicate that the CRH/β-endorphin pathway exerts a profound inhibitory action on the erectile response and both peptides act as principal mediators of stress-induced inhibition of sexual response.
In addition to psychogenic erection, physical stimulation of genital organs can elicit erections which are mediated by the S 2 -S 4 parasympathetic spinal centres of erection via the sacral spinal reflex pathway (reflexogenic erection) ( Figure 1 ). Thus, the erectile response is a combination of psychogenic and reflexogenic stimuli which result in an inhibition of thoracolumbar sympathetic (T 11 -L 2 ) and a stimulation of parasympathetic plus nonadrenergicnoncholinergic (NANC) (S 2 -S 4 ) fibre outflows. In particular, stimulation of parasympathetic and NANC fibre outflow determines the release of intrapenile vasoactive neurotransmitters, which are primarily acetylcholine (ACH), prostaglandins and nitric oxide (NO) (Steers, 1990) , and include other neuropeptides such as vasoactive intestinal polypeptide (VIP) (Yeh et al., 1994) . VIP is present in NO-synthesizing neurons projecting to the penis in rat (Vanhatalo et al., 1996) and humans (Tamura et al., 1995) , and may be an important contributor to penile erection in mammals (Yeh et al., 1994) . The release of these biochemicals inside the corpora, in turn, causes three complementary and simultaneous processes: arteriolar dilatation, relaxation of the smooth muscle within the corpora cavernosa and corporeal veno-occlusion (Saenz de Tejada et al., 1988) (Figure 1) . Contraction of the bulbocavernous and bulbospongiosus muscles allows further rigidity of the penis. Thereafter, relief of sympathetic inhibition and subsequent norepinephrine release leads to penile detumescence by producing marked vasoconstriction via norepinephrine activation of α 1 -adrenergic receptors.
Intracorporeal-produced endothelin-1 (ET-1) is a significant contributor to this mechanism. ET-1 released from endothelial cells, stretched following maximal dilation of the sinusoidal spaces, stimulates contraction of corpora cavernosa via activation of smooth muscle ET A -receptors, and synergizes the norepinephrine-induced detumescence (Saenz de Tejada et al., 1991) .
Psychoneuroendocrine causes of ED
An alteration of central regulatory mechanisms of sexual behaviour can result in ED. There is a large body of evidence that in the brain the concentration and the activity of several neuropeptides relevant for the control of sexual behaviour are regulated by testosterone and its metabolites (17β-oestradiol and 5α-dihydrotestosterone) (Freeman and Rissman, 1996) . Hypogonadal males have a reduced interest in sex, a decline in nocturnal penile erections and reduced semen volume, but they can retain erectile capacity to erotic stimuli depending on their concentrations of serum testosterone; below a testosterone threshold value of 1.4 ng/ml erectile function is lost (Carani et al., 1996) . Hypogonadal patients are responsive to testosterone replacement therapy in terms of restoring sexual desire and performance, in contrast to impotent men with normal circulating androgen concentrations in whom androgen therapy has no effect on erectile activity and is contraindicated (Robbins, 1996) . Hyperprolactinaemia does not appear to modify night erections or the penile response to video-erotic-stimulation, suggesting that its negative effect on libido and sexual behaviour is centrally mediated. This may occur through an increase of opioid tone and consequent alteration of pulsatile GnRH release (Quigley et al., 1980) . However, recent in-vitro experiments showed that acute infusion of prolactin caused a strong contraction of canine corpora cavernosa cells, suggesting a possible peripheral action of this hormone through not yet identified intrapenile receptors (Ra et al., 1996) .
Alteration of GnRH secretion has been suggested to be a possible cause of ED in men with non-organic impotence. We demonstrated that men with non-organic impotence have reduced serum LH biological activity and a low biological/immunological LH ratio (Fabbri et al., 1988) , and suggested that this may be due to changes in GnRH pulsatility possibly caused by an increased opioid tone. Subsequent experimental evidence indicated that restoration of adequate GnRH pulsatility in impotent men, for example, treatment with the opiate antagonist naltrexone, had important beneficial effects on erectile capacity (Fabbri et al., 1989b) .
Intracavernosal pharmacology of erection: NO pathway
NO is an important messenger molecule produced by endothelial cells, neurons, macrophages and other cells such as corpus cavernosum smooth muscle cells (Rajfer et al., 1992) . NO plays a key role in the human corpus cavernosum smooth muscle cell relaxation process (Lugg et al., 1995a) . Main sources of corporeal NO are (i) NANC nerves that end into penile arteries and trabeculae, (ii) endothelium of penile arteries and lacunar spaces, and (iii) smooth muscle cells (Figure 1 ). NO-synthase (NOS) catalyses the formation of NO through the enzymatic conversion of L-arginine to L-citrulline (Moncada, 1992) .
The three principal forms of NOS are the neuronal (nNOS or NOS-1), the macrophage or inducible (iNOS or NOS-2) and the endothelial (eNOS, or NOS-3) (Snyder, 1995) . NOS-1 and NOS-3 are constitutive (cNOS), cytosolic, Ca 2+ /calmodulin-dependent, and release NO for short periods in response to receptor or physical stimulation. NOS-2 (iNOS) is cytosolic, Ca 2+ -independent and is induced by cytokines and, once expressed, synthesizes NO for long periods. Emerging evidence indicate that iNOS occurs not only in macrophages but also in other cell types, including hepatocytes, chondrocytes, endothelial cells and fibroblasts. iNOS is not restricted to endothelial blood vessels, but exists in the epithelium of several tissues, including the bronchial tree. The NOS isozyme which functions in penile erection has not yet been clearly elucidated. Biochemical and histochemical evidence in rat and rabbit penis suggests that it belongs to both cNOS and iNOS (Lugg et al., 1995a) , and may be also to a recently identified additional NOS isoform (Magee et al., 1996) . NOS-containing neurons innervate the corpora cavernosa in the penis (Burnett et al., 1992) , and eNOS has been recently identified in the human corpus cavernosum smooth muscle cells by immunohistochemistry and electron microscopy (Seftel et al., 1996) . Garban et al. (1995a) demonstrated that in the penis of aged rats iNOS activity is reduced, and that the reduction is responsible for ED. The induction of iNOS gene expression within the penis restored potency in this animal model . nNOS does not seem to be important in penile erection since transgenic mice silenced for nNOS expression did show normal sexual behaviour (Huang et al., 1993) . However, the identification of a novel nNOS species in rat penis, designated as penile-NOS (PnNOS; Magee et al., 1996) , indicates that this new isoform may be important in penile erection. Evidence suggests that in rats NO production is regulated by androgens (Mills et al., 1996) , in particular testosterone and dihydrotestosterone (Garban et al., 1995b; Lugg et al., 1995b; Reilly et al., 1997) , and that a defect in NO production may be consequent to reduction in circulating androgens, such as in diabetes mellitus (Saenz de Tejada et al., 1989) . Another regulator of NO production is the intrapenile molecular oxygen tension (Kim et al., 1993) , which also modulates the local production of transforming growth factor-β (TGF-β). Cavernous body-derived TGF-β is involved in the fibrotic degeneration of smooth muscle cells in the corpora of impotent men (Moreland et al., 1995) , and is highly expressed in those of subjects affected by Peyronie's disease and veno-occlusive dysfunction (Gentile et al., 1996) . In these latter diseases, the imbalance of smooth-muscle:connective tissue ratio in the trabeculae may be due to a low oxygen tension in the corpora, with a consequent TGF-β overproduction and inhibition of prostaglandin synthesis (Nehra et al., 1996) . Since cAMP is the most potent inhibitor of TGF-β, therapeutic agents that stimulate intracorporeal cAMP production [i.e. prostaglandin (PG)E 1 , forskolin, phosphodiesterase inhibitors], have been indicated as potential treatments for ED due to fibrosis of human corpus cavernosum.
Penile erection is the result of a complex balance between intracellular events and extracellular signals controlling contraction and relaxation of smooth muscle cells (SMCs) tone (Andersson and Wagner, 1995) . Contraction follows the activation of the α 1 -adrenergic receptor by norepinephrine, or by ET-1 activation of the ET A receptor. In both cases, receptor activation leads to Ca 2+ mobilization. Specifically, activation of these receptors by NE and ET-1 leads to activation of phospholipase C, which cleaves membrane-bound phosphatidyl inositol (PIP 2 ) into inositol trisphosphate (IP 3 ) and diacylglycerol (DAG), resulting in an elevation of intracellular calcium concentrations (Zhao and Christ, 1995) (Figure 1 ). Relaxation may be induced by two different pathways: (i) stimulation of the PGE 1 receptor activates the adenylate cyclase enzyme, which catalyses the conversion of ATP to cAMP, leading to an increase in intracellular cAMP and stimulation of protein kinase A (PKA) and (ii) NO release from endothelial or neuronal sources activates soluble guanylate cyclase, which in turn catalyses the conversion of GTP to cGMP. Increased intracellular cGMP concentrations activate protein kinase G (PKG), with a diminution of transmembrane Ca 2+ flux, sequestration of intracellular Ca 2+ , membrane hyperpolarization and smooth muscle cell relaxation (Christ, 1995) . The effects of PKA, PKG and protein kinase C on gap junctions, K + channels, and Ca 2+ channels are thought to be mediated via phosphorylation of specific amino acid residues on target proteins (gap junctions, K + channels and Ca 2+ channels) (Moreno et al., 1993) . Gap junctions and potassium and calcium channels are major modulators of smooth muscle cell tone in the corpora (Fan et al., 1995) . In particular, recent studies have indicated the importance of the maxi-K channel and K ATP channel subtypes in the modulation of smooth muscle cell tone, suggesting a possible pathophysiological role in ED (Christ et al., 1997) .
Peripheral causes of ED
Peripheral causes of cavernous ED can be classified into five types (Lue, 1994) : (i) large veins exiting the corpus cavernosum (probably congenital when noted in young men), (ii) enlarged venous channels caused by distortion of the tunica albuginea, as in Peyronie's disease or the weakening associated with ageing, (iii) the inability of cavernous smooth muscle to relax due to fibrosis, degeneration or dysfunction of gap junctions, (iv) inadequate release of neurotransmitters, mainly NO (in neurogenic or psychogenic impotence or endothelial dysfunction) and (v) abnormal communication between the corpus cavernosum and spongiosum or glans (either congenital, traumatic or after a shunt procedure for priapism).
Diagnostic approach
A correct approach to the impotent patient will enable the physician to clarify rapidly the aetiology of ED. Medical history must be aimed to evaluate the presence of risk factors, associated diseases and drug consumption. A slowly progressive loss of erectile function associated with absent nocturnal erections is often due to organic causes. An abrupt onset of sexual complaints associated with maintained nocturnal erections is strongly suspicious of a psychogenic cause. Nonetheless, physical examination represents a crucial step in identifying possible hypogonadal features (i.e. small testicles, gynaecomastia and/or galactorrea, hair loss in androgen-dependent areas), as well as the presence of penile fibrotic plaques. Some degree of lateral penile deviation may be observed at genital inspection; this finding is common, is an aspect of genital asymmetry in men, and has no functional consequences for erection (Bogaert, 1997) .
The practical purpose of diagnostic testing in our outclinic patients is to rule out endocrinopathies and to assess maximal erectile capacity in order to establish the optimal treatment. There is no single test that enables the physician to discriminate the origin and degree of impotence. The clinical approach to ED has become less invasive and more standardized, with the use of the pharmaco-erection test and pharmaco-penile duplex ultrasonography (PPDU), along with nocturnal penile tumescence and rigidity (NPTR). The pharmaco-erection test and PPDU represent a first-line non-invasive approach to investigate arterial and veno-occlusive function. A lack of full erectile response after a pharmaco-erection test with a maximal PGE 1 dose frequently occurs during outpatient evaluation because the test itself represents a stressful event. Erectile response can be maximized by using a cocktail of 20 µg/ml PGE 1 plus 0.5 mg/ml phentolamine (Aversa et al., 1996a) . To date, a positive response to the pharmaco-erection test in terms of rigidity and duration implies normal veno-occlusive mechanisms but is an inadequate discriminant of arterial disease (Pescatori et al., 1994; Cormio et al., 1996) . To evaluate cavernous artery inflow and veno-occlusive function, PPDU is performed in combination with genital and audio-visual sexual stimulation (Montorsi et al., 1996) . Also, in order to standardize the genital stimulation, vibrotactile devices should be used (Incrocci et al., 1996) . The generally accepted normal limit for arterial function after PPDU (cavernous peak blood flow velocity >25-30 cm/s) must be interpreted carefully because lower peak blood velocities may be found in subjects with a full erectile response if valid arterial communications are present (Mancini et al., 1996) . Veno-occlusive dysfunction is suspected when end-diastolic flow velocity exceeds 5 cm/s and the resistance index (i.e. peak flow velocity ±diastolic flow velocity/peak flow velocity) is <0.90 (Quam et al., 1989) . When the maximum erection obtained at the end of these tests is lower than that obtained at home, the patient should undergo repeated intracavernous injections by using a combination of PGE 1 plus phentolamine or PGE 1 plus papaverine plus phentolamine followed by genital and audio-visual stimulation until an optimal erection is achieved (Aversa et al., 1996a) . If this procedure fails, pharmaco-cavernosometry, performed during a phase of continuous linearity in the ratio between intracavernous pressure and maintenance flow, represents the only test that avoids the bias of a false-positive diagnosis of veno-occlusive dysfunction.
Neurological investigations should be principally reserved for subjects with suspected or overt neurogenic ED, i.e. those with a history of discopathies of lumbosacral tract, pelvic surgery, alcohol and drug abuse, diabetes and spinal cord injury. In these latter patients, sexual dysfunction and ejaculatory disorders occur to different extents, depending on the level and severity of cord lesion (Yalla et al., 1993) , and can be treated with personalized pharmaco-erection programmes (Sidi et al., 1987) and assisted ejaculation techniques (Denil et al., 1996; Hultling et al., 1997) . Diagnostic tests include measurement of the vibratory threshold of the penile glans and the pudendal somatosensory evoked potentials (assessment of somatosensory pathways), bulbocavernous reflex (somatosensory afferents, spinal circuits and somatomotor efferents) and urethroanal reflex (autonomic sensory afferents) (Bemelmans et al., 1995) . Electromyography of the penile corpus cavernosum has been recently proposed as a new sensitive diagnostic tool to evaluate cavernous smooth muscle content and its autonomic innervation (Merckx et al., 1996) . Some evidence suggests that type-1 diabetic patients should undergo a complete neurological study because it has been shown that peripheral and urogenital autonomic sensory neuropathies are a major cause of ED, especially in the presence of poor glycaemic control (Bemelmans et al., 1994) . On the other hand, ED in type-2 diabetic patients appears to be mainly due to vascular rather than neurological factors (Aversa et al., 1996b) .
Psychological investigation can be performed using instruments to quantify sexuality and sexual dysfunction (Derogatis Sexual Functioning Index; Derogatis and Melisaratos, 1981) and scales of personality (Minnesota Multiphasic Personality Inventory; Beutler et al., 1975) . However, these questionnaires are lengthy, of limited use when repeated measures are required and, like all other inventories, inaccurate in discriminating between organic and psychogenic aetiologies (Gregoire, 1993) . Thus, a preferred strategy is to investigate specifically marital disharmony, depression and anxiety levels using selective and specific self-rating scales in order to detect psychological and psychiatric morbidity. With this aim, appropriate, simple and rapid questionnaires can be administered (Gregoire, 1993; Aversa et al., 1996a) ; these include the Golombock-Rust Inventory of Marital State (GRIMS) for marital satisfaction (Rust et al., 1986 ), Zung's test for depression (Zung, 1970) and the State-Trait Anxiety Inventory (STAI) for anxiety (Spielberger et al., 1970) .
NPTR is an objective and valuable tool for differentiating between psychogenic and organic impotence, although its validity has been questioned. The majority of men with organic impotence also have a significant psychogenic component which is likely to exacerbate the effects of the underlying organic factors. Limitations of NPTR are represented by the inability to assess the adequacy of sleep, the difficulty in distinguishing arterial from venous causes, and the presence of impaired NPTR in up to 20% of subjects with no identifiable evidence of organic disease, or of a fairly normal NPTR in the presence of organic disease (Levine and Lenting, 1995) . Our personal approach to evaluate the impotent patient is to recommend NPTR as a second-line investigation to confirm the diagnosis of psychogenic ED, with the exception of those cases in which young age, absence of risk factors, no drug consumption and no associated diseases suggest a different approach (Figure 2) . Sexology counselling should be advised as it can help in investigating possible disorders in a couple's relationship.
Endocrine evaluation should be carried out in all impotent patients since endocrine dysfunction is not uncommon, occurring in from 1 to 35% of the study population. Two consecutive blood determinations of prolactin and total and free testosterone are recommended. We recently observed that up to 20% of elderly impotent patients had high oestradiol concentrations and an impaired erectile response to the pharmaco-erection test, possibly because of their impaired testosterone/oestradiol ratio, so that determination of oestradiol is also suggested (Aversa et al., 1996c) . When total and/or free testosterone concentrations are abnormal, gonadotrophin determination should be performed. In addition, a measurement of the blood sugar concentration should be obtained since ED may represent the initial symptom in 5-10% of newly diagnosed diabetic patients. Determinations of thyroid hormones and cortisol should be reserved as second-line tests only for those patients in whom clinical features suggest a possible underlying disease.
Therapies
The past two decades have been characterized by a radical change in the treatment of ED. During the late 1970s, penile implants represented the only alternative to Figure 2 . Diagnostic algorithm of erectile dysfunction. T = total testosterone; FT = free testosterone; PRL = prolactin; FSH = follicle stimulating hormone; LH = luteinizing hormone; TSH = thyrotrophic-stimulating hormone; FT 3 = free T 3 ; MRI = magnetic resonance imaging; PGE 1 = prostaglandin E 1 ; PPDU = pharmaco-penile duplex ultrasonography; VOD = veno-occlusive dysfunction; NPTR = nocturnal penile tumescence and rigidity. revascularization or venous ligation procedures; these latter procedures were affected by a high incidence of relapse after surgery. In the early 1980s, the advent of vacuum device therapy and intracavernous injection of vasoactive drugs (i.e. papaverine; Virag, 1982) made the management of impotent patients less invasive. During the late 1980s, PGE 1 administered by intracavernous injection was introduced, becoming in the early 1990s the drug of choice for self-injection therapy, alone or in combination with papaverine and phentolamine. In erectile failure, intracavernous PGE 1 therapies show a response rate of >70% (up to 92% if used in combination with papaverine and phentolamine) and a considerably lower risk of priapism as well as of local fibrotic complications when compared to papaverine with phentolamine (0.3 versus 6% and 0.8-7.5 versus 12.4% respectively). Prolonged treatment with intracavernous PGE 1 has been reported to improve blood flow in the deep penile arteries (Marshall et al., 1994) . Except for rare cases of reduced blood pressure, no important systemic side-effects have been observed after a single intracavernous injection of PGE 1 . Pain at the site of injection represents the most common side-effect (25-30%), which decreases to 7-10% after 3 years of therapy (Porst, 1996a) . Recently, the American Urological Association elaborated a Clinical Guidelines Panel for the management of erectile dysfunction and recommended three treatment alternatives: vacuum constriction devices, intracavernous injection of vasoactive drugs and penile prosthesis implantation (Montague et al., 1996) .
Orally active drugs (i.e. yohimbine, trazodone, pentoxifylline) do not appear to be effective for treatment of vasculogenic erectile dysfunction, and thus they are not recommended as treatment for the standard patient. Only patients with overt hypogonadism benefit from testosterone replacement therapy. It has been demonstrated that the recently developed transdermal systems of testosterone delivery allow a more physiological restoration of blood androgen concentrations than the use of intramuscular esters in long-term androgen replacement therapy (Arver et al., 1996) . The treatment of choice for prolactinomas of all sizes is a dopamine agonist, such as bromocriptine (2.5-20 mg per day) or cabergoline (0.5-2 mg twice a week), which can shrink adenomas and lead to resolution of microadenomas. In rare cases, transphenoidal surgery is necessary in the treatment of a macroadenoma, when dopamine agonist therapy has failed. In young men with psychogenic impotence, treatment with orally active drugs may be performed. Yohimbine at high doses (15-45 mg per day, for at least 3 months) (Susset et al., 1996) and naltrexone (50 mg per day for 3 weeks) (Fabbri et al., 1989a) have been shown to be effective in >50% of patients, with mild to moderate side-effects. Topical application of creams containing different vasodilator agents, i.e. nitroglycerine alone or in combination with aminophylline and co-dergocrine, should be considered as an effective alternative treatment, particularly in patients with psychogenic ED (Gomaa et al., 1996) .
Surgical treatments such as venous and arterial surgery are considered investigational and should be performed only in a research setting where long-term follow up is available (De Palma, 1997) .
Future therapies
Future therapies include agents acting locally in the corpora cavernosa and oral drugs. Since the dropout rate for intracavernous self-injection therapy remains high, alternative and less invasive local treatments for ED have been studied. Transurethral administration of PGE 1 has been suggested as a new possibility in the management of impotent patients (Padma-Nathan et al., 1997) . After clinic and home testing, 65% of impotent men reported having sexual intercourse after transurethral administration of 125-1000 µg PGE 1 , with a mean time to onset of erection of 7 min and a mean duration of 70 min. Most important, transurethral PGE 1 had minimal side-effects (transient mild local pain in 1/3 of patients treated) and did not cause penile fibrosis, which in contrast occurs at variable percentages (up to 7.5%) with long-term intracavernous administration of PGE 1 .
Future oral therapies include (i) phosphodiesterase (PDE) inhibitors, (ii) dopaminergic agents, (iii) α-blockers, (iv) neuropeptides.
PDE inhibitors
PDE inhibitors are a group of new therapeutic agents that block cGMP degradation via PDE inhibition and by this mechanism enhance the effect of NO in inducing smooth muscle relaxation and erection (Boolell et al., 1996) . Five different PDE isoforms (PDE1-PDE5) have been described and found to be present at various concentrations in human tissues. The main PDE activity in human corpus cavernosum is due to PDE5, with PDE2 and PDE3 also identified (Stief et al., 1996) . The observation of specific PDE isoform distribution inside human corpora cavernosa led to the study of a possible use of a potent and selective inhibitor of the cGMP-PDE5 (UK-92-480, sildenafil) in the treatment of male erectile dysfunction. Ballard et al. (1996) were the first to report that sildenafil (Viagra ® ; Pfizer, Sandwich, UK), a selective inhibitor of PDE5, stimulates smooth muscle cell relaxation in vitro. Successive studies in humans have demonstrated that the oral administration of sildenafil is effective in inducing erectile response to video-sexual-stimulation in terms of duration and rigidity, thus highlighting the role of PDE5 in human penile erection. Preliminary results from multicentre trials suggest that oral sildenafil treatment (25-100 mg before intercourse) represents a safe and well-tolerated therapy, highly effective in restoring sexual activity (i.e. occurrence of satisfactory sexual intercourse in ~80% of patients with unknown organic types of impotence and in >95% of patients with psychogenic impotence). The most common adverse events reported were headache, flushing, visual disturbances, dyspepsia and muscle aches. Further studies on the pharmacokinetics and safety of the drug are in progress.
Dopaminergic agents
The aphrodisiac effects of apomorphine (APO) alkaloids, central dopaminergic-receptor agonists derived from waterlily tubers, have been known for several centuries. The effects of different doses of oral APO on erectile function have been recently investigated in humans. Initially, it was suggested that APO acted peripherally via the parasympathetic nerve system. Recently it has been demonstrated that the erectogenic effect of APO occurs centrally through stimulation of transcription of the early gene c-fos in some critical brain structures of the rat, i.e. the bed nucleus of the stria terminalis, preoptic area, supraoptic nucleus, paraventricular nucleus of the hypothalamus, central and medial nuclei of the amygdala, raphe, Barrington's nucleus/lateral dorsal tegmental region, parabrachial nucleus and nucleus of the solitary tract (Drolet et al., 1996) . Clinical trials are in progress with sublingual tablets containing 2, 4 and 6 mg APO. Preliminary results of these studies performed in men with non-organic impotence showed satisfactory erections in up to 70% of patients in home use. However, adverse events were reported by >50% of patients, i.e. nausea, yawning and drowsiness .
α-Adrenergic antagonists
The α-adrenergic receptor antagonist phentolamine has been widely used for intracavernous vasoactive injection therapy and it has been suggested that its systemic administration may exert both central and peripheral erectogenic effects. Phentolamine at a dose of 40-60 mg administered buccally before sexual intercourse resulted in satisfactory erections in ~50% of subjects with organic impotence without producing any important side-effects (Porst et al., 1996b) . Clinical trials with sublingual phentolamine are in progress.
Others
Another promising drug in the treatment of ED is represented by melanotropic peptide (α-MSH). Subcutaneous α-MSH administration in men with non-organic impotence has been shown to be highly effective in inducing full and sustained erections in the presence of mild to moderate yawning and facial flushing (Wessells et al., 1996) . Oxytocin administration should be kept in consideration in view of its stimulatory effects on animal copulatory behaviour. However, this hormone is not available for oral or intranasal administration, and controlled studies in humans have not been performed yet, but should be encouraged.
Conclusions
The approach for diagnosis of ED has evolved since the recent introduction of non-invasive diagnostic techniques such as the pharmaco-erection test and pharmaco-penile duplex ultrasound. These tests enable a complete study of arterial and veno-occlusive function, and corporal integrity. Furthermore, routine endocrine screening is an essential element in the evaluation of male sexual function. Also, psychological assessment is recommended in order to better select the appropriate therapy. Neurological testing is performed only in a selected group of patients.
The use of vasoactive drugs for self-injection therapy has revolutionized the era of penile implants, and the recent availability of an intraurethral suppository for the administration of PGE 1 has made this therapy minimally invasive. Surgical therapy is still necessary in those patients with congenital or acquired vascular or corporeal damage. However, the development of orally active and safe drugs, such as PDE inhibitors, appears to be of great promise in the future for the medical treatment of erectile dysfunction. Finally, recent discoveries in the research into the intracavernous mechanisms that lead to erection have shown that NOS deficiency in human corpora cavernosa plays an important role in the development of erectile dysfunction. These findings, coupled with recent advancements in molecular biology techniques, might open new aspects in the treatment of male impotence, such as the use of gene therapy and/or the development of drugs capable of inducing intracorporeal NOS.
